RNA Interference (RNAi)

Core Concept

RNA interference (RNAi) is a conserved mechanism in which small double-stranded RNA molecules direct the silencing of complementary messenger RNAs, reducing the amount of a specific protein. Exogenous siRNA (or vector-encoded shRNA) is processed and loaded into the RNA-induced silencing complex (RISC); the "guide" strand pairs with a complementary mRNA, and the Argonaute protein in RISC cleaves that mRNA or represses its translation. The result is a knockdown — a transient, partial loss of the gene product at the mRNA level. RNAi does not alter the gene itself, so it is fundamentally different from a knockout, which deletes or disables the DNA.

Key Components

siRNA / shRNA

• siRNA: ~21–23 nucleotide double-stranded RNA introduced into cells; one strand becomes the guide.
• shRNA: a short hairpin RNA expressed from a DNA vector, processed into an siRNA-like duplex for sustained knockdown.

Dicer

• An RNase III enzyme that cleaves long double-stranded RNA (or shRNA hairpins) into ~21–23 nt small interfering RNA duplexes.

RISC and Argonaute (Ago2)

• RISC is the effector complex; Argonaute is its catalytic "slicer" component. The guide strand is loaded into RISC, which then finds and cleaves complementary mRNA.

Guide strand (vs. passenger strand)

• Only the strand whose 5′ end is less stably paired is retained as the guide; the passenger strand is discarded.

miRNA (endogenous counterpart)

• MicroRNAs are genomically encoded small RNAs that regulate many endogenous mRNAs, usually by imperfect pairing and translational repression; RNAi harnesses the same machinery.

Mechanism

1. Entry/processing. Synthetic siRNA (already short) enters the cell, or shRNA/long dsRNA is cut by Dicer into ~21–23 nt duplexes.
2. RISC loading. The duplex is loaded into RISC; the passenger strand is removed, leaving the guide strand bound to Argonaute.
3. Target recognition. The guide strand base-pairs with a complementary sequence in a target mRNA (perfect pairing → cleavage; imperfect → translational repression and/or destabilization).
4. Silencing. Argonaute cleaves the mRNA (or blocks translation), and the fragments are degraded; protein output from that gene falls.
5. Phenotype. The cell shows reduced levels of the target protein over days, mimicking a loss-of-function phenotype (transiently and partially).

Energy and Directionality

RNAi is powered by the cell's normal energy currency. Dicer and Argonaute-catalyzed mRNA cleavage are ATP-independent reactions, but the processes that support and sustain silencing — RISC assembly, helicase-mediated unwinding of the duplex, and mRNA degradation — are coupled to ATP (and GTP) hydrolysis. Directionality is enforced by guide-strand selection and by base-pairing: the guide reads the mRNA in an antiparallel, sequence-specific manner, so only complementary transcripts are silenced.

Experimental Evidence

• What it measures: the functional consequence of reducing a specific mRNA/protein (a knockdown).
• Principle: small RNA-guided, Argonaute-mediated cleavage/repression of complementary mRNA.
• Input: siRNA/shRNA targeting the gene of interest; control siRNA. Output: reduced target mRNA (by RT-qPCR) and protein (by Western blot), and an associated phenotype.
• What it can prove: that lowering a gene product causes (or fails to cause) a phenotype — evidence of its function, often in loss-of-function terms.
• What it cannot prove: complete loss-of-function (knockdown is partial and transient); it cannot distinguish whether residual protein masks a phenotype; off-target effects (silencing unintended mRNAs) can confound results; and it says nothing about effects that require full, permanent gene removal.
• Controls: non-targeting/scrambled siRNA (rules out general RNAi toxicity); untreated/mock-transfected cells; rescue (re-express an siRNA-resistant version of the gene to show the phenotype is specific); measuring knockdown efficiency by RT-qPCR (mRNA) and Western blot (protein); multiple independent siRNAs against the same target (to control off-target effects).
• Common mistakes: reporting a phenotype without confirming knockdown actually occurred; using one siRNA only (off-target risk); confusing knockdown with knockout; and assuming protein loss equals mRNA loss without verifying.

Common confusions

• "RNAi is a knockout" — No. Knockout alters the DNA (permanent); RNAi degrades mRNA (transient, partial knockdown).
• "siRNA, shRNA, and miRNA are the same" — siRNA is synthetic dsRNA; shRNA is a vector-expressed hairpin; miRNA is a genomically encoded endogenous regulator. All feed the RISC pathway.
• "Knockdown of mRNA automatically means no protein" — Some protein may persist or be compensated; verify protein levels.
• "One siRNA is enough proof" — Off-target effects can mislead; use multiple siRNAs and rescue experiments.
• "RNAi proves a gene is essential" — It shows reduced product changes a phenotype; only a clean knockout/knock-in (e.g., CRISPR) establishes necessity rigorously.

Quick review

• siRNA/shRNA → Dicer (if needed) → RISC/Argonaute → guide strand binds complementary mRNA → cleavage/repression → less protein.
• Knockdown ≠ knockout; transient and partial.
• Controls: scrambled siRNA, mock, rescue, RT-qPCR + Western confirmation, multiple siRNAs.